John Lee
2021 - PhaseBio Pharmaceuticals
In 2021, John Lee earned a total compensation of $856.3K as Chief Medical Officer at PhaseBio Pharmaceuticals, a 6% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $192,003 |
---|---|
Option Awards | $207,414 |
Salary | $442,900 |
Other | $13,981 |
Total | $856,299 |
Lee received $442.9K in salary, accounting for 52% of the total pay in 2021.
Lee also received $192K in non-equity incentive plan, $207.4K in option awards and $14K in other compensation.
Rankings
In 2021, John Lee's compensation ranked 9,277th out of 12,415 executives tracked by ExecPay. In other words, Lee earned more than 25.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 9,277 | 25th |
Manufacturing | 4,113 | 25th |
Chemicals And Allied Products | 1,813 | 24th |
Drugs | 1,610 | 23rd |
Pharmaceutical Preparations | 1,194 | 23rd |
Lee's colleagues
We found two more compensation records of executives who worked with John Lee at PhaseBio Pharmaceuticals in 2021.
News
Marathon Patent Group CFO Hugh Gallagher receives $4.8M in 2022
June 23, 2023
Decibel Therapeutics CEO Laurence Reid's 2022 pay jumps 54% to $1.2M
April 28, 2023
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2021 pay slips 13% to $1.5M
April 22, 2022
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2019 pay jumps 102% to $1.2M
April 24, 2020
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2018 pay jumps 37% to $596K
April 5, 2019